Archives of Pharmacology and Therapeutics

Review Article Open Access

Why Can Modulation of α6-Containing GABA_A Receptors Reduce the Symptoms of Multiple Neuropsychiatric Disorders?

Werner Sieghart

α6-containing GABA_A receptors (α6GABA_ARs) are strongly expressed in cerebellar granule cells, where they mediate a correctly timed and precise coordination of all muscle groups that execute behavior and protect the brain from information overflow. Recently, it was demonstrated that positive modulators with a high selectivity for α6GABA_ARs (α6-modulators) can reduce the symptoms of multiple neuropsychiatric disorders in respective animal models to an extent comparable with established clinical therapeutics.

Review Article Open Access

Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments

Ilana P. Goldberg, Benjamin Lichtbroun, Eric A. Singer, Saum Ghodoussipour

Bladder cancer is the sixth most common malignancy in the United States and 70% of cases are non-muscle invasive at the time of diagnosis. Effective treatment is crucial to prevent progression, which occurs in about 30% of patients. The American Urological Association (AUA) guidelines recommend treatment of non-muscle invasive bladder cancer (NMIBC) with intravesical Bacille Calmette-Guerin (BCG) and chemotherapy.

Research Article Open Access

Relative COVID-19 Vaccine Booster Effectiveness and ClinicalEpidemiological Characteristics Before and After 29 Days of Shot

Jose Luis Turabian

Background: When the highest vaccine COVID-19 booster effectiveness (VBE) is obtained is not clearly known. Objective: To compare the cases of COVID-19 in booster vaccinated people with a time of <29 days vs. ≥ 29 days from booster to infection diagnosis and assess their relative VBE. Methodology: An observational, longitudinal and prospective case series study of adult patients with COVID-19 breakthrough infections in booster vaccinated people, in general medicine and for the period December 2021 to February 2022, during the omicron variant contagion wave.

Research Article Open Access

ProLung™-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation

Kameswari S. Konduri, Ram Pattisapu, Jogi Pattisapu, Girija G. Konduri, John Zwetchkenbaum, Bidhan Roy, Monalisa Barman, Adria Frazier, Brett L. Hurst, Nejat Duzgunes

Inhaled budesonide benefits patients with COVID-19. ProLung™-budesonide enables the sustained, low dose administration of budesonide within a delivery vehicle similar to lung surfactant.

Editorial Open Access

COVID-19 Disease and SARS-CoV-2 Vaccination in Patients with Cancer

Daniel A. King, Jeffrey Chi, Shreya Prasad Goyal, Muhammad Wasif Saif

Since the declaration of COVID-19 as a pandemic in March 2020 [1], there have been more than 100 million reported cases of COVID-19 worldwide and more than 2.1 million deaths [2].

Brief Report Open Access

Pharmacogenetic Variants in the DPYD and TYMS Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice

Muhammad Wasif Saif, Hilal Hachem, Sneha Purvey, Ruchi Hamal, Lulu Zhang, Nauman Saleem Siddiqui, Amandeep Godara, Robert B. Diasio

Fluoropyrimidines have been extensively used for almost 6 decades to treat a variety of solid cancers, especially colon, gastric, anal, rectal, head & neck and breast. However, 31–34% of patients encountered grade 3–4 adverse events (AEs) with 0.5% mortality oftennecessitating dose reduction or discontinuation.